Brittany Meiling – Page 10 – Endpoints News

about the author

Brittany Meiling

editors@endpointsnews.com

Brittany Meiling on LinkedIn

author articles

Alzheon files for $80M IPO to take once-failed Alzheimer's drug into PhIII

8 years ago

FDA OKs Hizentra for rare autoimmune disease CIDP

8 years ago

Loncar Investments launches China biopharma index; La Jolla prices $100M public offering

8 years ago

J&J's blockbuster hopeful erdafitinib gets 'breakthrough' moniker

8 years ago

China stocks the new trend? Loncar launches index

8 years ago

'Right-to-try' bill fails to muster votes, dies in the House (for now)

8 years ago

An immunotherapy pill for psoriasis? Escalier gets $19M Series B to tackle R&D

8 years ago

FDA gives priority review to new Keytruda sBLA; AstraZeneca's Pearl signs asthma development pact with Avillion

8 years ago

With rival to anti-TNF injectables, Protalix reports positive PhII data in ulcerative colitis

8 years ago

Proteostasis stock soars on cystic fibrosis breakthrough status

8 years ago

Sarepta plays nice with the FDA, sets out plans for second accelerated Duchenne pitch by year's end

8 years ago

Bitter board members at Arcturus head to legal office to vote on directors

8 years ago

With debt looming, browbeaten diet pill maker Orexigen goes bankrupt -- shares slide

8 years ago

Martin Shkreli sentenced to 7 years on felony fraud convictions

8 years ago

Voyager's gene therapy for Parkinson's shows promise in early data from small Phase Ib trial

8 years ago

Xeris hauls $55M in new funding to bring glucagon pen to market

8 years ago

Novartis joins forces with LA tech company Science 37 to launch virtual clinical trials

8 years ago

SF tech startup Atomwise gets $45M for AI-powered drug design software

8 years ago

As killer virus outbreaks hit unprecedented levels, nonprofit hands $37.5M to Themis to tackle Lassa/MERS vaccines

8 years ago

After bagging Shire’s cell therapy castoff, Caladrius stock climbs

8 years ago

Cambridge star Magenta teams up with Heidelberg on bone marrow R&D pact that includes $334M in potential milestones

8 years ago

Stock flies high on Clearside’s PhIII macular edema trial results as drug improves vision

8 years ago

Is tech money bad for business? Silicon Valley cash makes some biopharma VCs bristle, others cheer

8 years ago

Perlara collaborates with Harvard/Undiagnosed Diseases Network; Verona shares soar on positive CF data

8 years ago

First page Previous page 7 8 91011 12 13 Next page Last page